Scientific Studies

Unlike many other food supplements, Bimuno® is underpinned by a large and growing body of published scientific evidence.


The effects of a trans-galacto-oligosaccharide (B-GOS) prebiotic on faecal microbiota and symptoms in irritable bowel syndrome


Background: Gut microflora-mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS).

Aim: To investigate the efficacy of a novel prebiotic trans-galactooligosaccharide (B-GOS) in changing colonic microflora and improve the symptoms in IBS sufferers.

Methods: In all 44 patients with Rome II positive IBS completed a 12 week single centre parallel crossover controlled clinical trial. Patients were randomized to receive either 3.5g/d prebiotic, 7g/d prebiotic or 7 g/d placebo.

IBS symptoms were monitored weekly and scored according to a 7 point Likert scale. Changes in faecal microflora, stool frequency and form (Bristol stool scale) subjective global assessment (SGA), anxiety and depression and QOL scores were also monitored.

Results: The prebiotic significantly enhanced faecal bifidobacteria (3.5g/d P<0.005; 7g/d P<0.001). Placebo was without effect on the clinical parameters monitored, while the prebiotic at 3.5g/d significantly changed stool consistency (P<0.05), improved flatulence (P<0.05), bloating (P<0.05), composite score of symptoms (P<0.05) and SGA (P<0.05). The prebiotic at 7g/d significantly improved SGA (P<0.05) and anxiety scores.

Conclusion: The galactooligosaccharide acted as a prebiotic in specifically stimulating gut bifidobacteria in IBS patients and is effective in alleviating symptoms. These findings suggest that the prebiotic has potential as a therapeutic agent.


Silk DBA et al. Aliment Pharmacol Ther 2009;29:508-518.




Back to Scientific Studies


This section is an information and educational resource for healthcare professionals, scientists, researchers and journalists. It is not intended for consumers. If you wish to purchase Bimuno please click here

Back to the top